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Abstract (250 words) 39 
 40 
 41 
Background: Heart failure with preserved ejection fraction (HFPEF) is common but no treatment has 42 
yet been shown to improve symptoms or prognosis. The pathophysiology of HFPEF is complex but 43 
characterized by increased left atrial pressure, especially during exertion, which may be a key 44 
therapeutic target. 45 
 46 
Methods: The REDUCE LAP-HF (REDUCe Elevated Left Atrial Pressure in Patients with Heart 47 
Failure) study was an open-label single arm study designed to evaluate the performance and safety of 48 
a trans-catheter inter-atrial shunt device (IASD, Corvia Medical) in patients with symptoms of HFPEF 49 
despite pharmacological therapy, LVEF>40%, and an elevated pulmonary capillary wedge pressure 50 
(PCWP) at rest (>15mmHg) or during exercise (>25mmHg). The primary objectives were to assess 51 
device safety and performance at six months, together with measures of clinical efficacy, including 52 
functional capacity and clinical status. 53 
 54 
Findings: IASD placement was successful in 64 patients (mean age 69±8years; 66% women; median 55 
[IQR] NT-proBNP 377 [222-925] pg/ml) and appeared safe and well tolerated. Sustained device 56 
patency was confirmed by left-to-right shunting (pulmonary/systemic flow: 1.06±0.32 baseline; 57 
1.27±0.20 at 6 months; p=0.0004). Exercise PCWP was lower at 6 months at 20 watts (32±8 vs 29±9; 58 
p=0.0124) and peak (34±8 vs32±8; p=0.0255) despite increased exercise duration (7.3±3.1 vs 59 
8.2±3.4 minutes, p=0.03). Minnesota quality of life scores (49±20 vs 36±23, p<0.0001) and 6 minute 60 
walk distance (313±105 vs 345±106 metres (p=0.0023) had improved by six months. 61 
 62 
Interpretation: Implantation of an interatrial shunt device is feasible, appears safe, reduces left atrial 63 
pressure during exercise and may be a novel strategy for the management of HFPEF. The 64 
effectiveness of IASD compared to current therapy for patients with HFPEF requires validation in a 65 
randomized controlled trial. 66 
 67 
Funding: Corvia Medical Inc. (Formerly DC Devices Inc.) 68 
 69 




Many patients with symptoms of heart failure do not have evidence of reduced left ventricular systolic 73 
function; a syndrome which has been termed heart failure with preserved ejection fraction (HFPEF) 
1,2
 74 
to distinguish it from those with heart failure and a reduced ejection fraction (HFREF). Epidemiological 75 
studies suggest that the incidence of HFPEF is rising 
3,4
, although it is unclear whether this is primarily 76 
due to improved recognition, the presence of an aging population or increases in the prevalence of 77 
co-morbid diseases such as hypertension, chronic kidney disease and diabetes; each likely  making a 78 
contribution. 79 
 80 
Whilst pharmacological treatment has improved symptoms and reduced morbidity and mortality for 81 
patients with HFREF, finding an effective treatment for patients with HFPEF has proved elusive 
5-10
. 82 
The hallmark of HFPEF is effort intolerance which is associated with a profound and rapid increase in 83 
left atrial pressure during exercise reflecting impaired left ventricular diastolic reserve
11,12
, with 84 
consequent pulmonary congestion. This disproportionate rise in left atrial pressure is thought to 85 




In 1916, Lutembacher described the combination of mitral stenosis, which mimics some of the 88 
pathophysiology of HFPEF, and an atrial septal defect (ASD). Patients with Lutembacher’s syndrome 89 
may have fewer symptoms and better outcomes compared with patients with pure mitral stenosis and 90 
closure of their ASD may cause a rise in pulmonary artery pressure and pulmonary oedema in some 91 
patients. An iatrogenic left to right atrial shunt is thus a potentially attractive intervention which might 92 
have therapeutic value. Haemodynamic modelling based upon clinical measurements suggests that 93 
an appropriately-sized iatrogenic ASD could attenuate exercise induced increases in left atrial 94 
pressure in patients with HFPEF 
14
. We postulated that a novel device-based therapy targeting a 95 
common pathophysiologic feature of HFPEF might succeed where pharmacological therapies have 96 
failed. The REDUCE LAP-HF study (REDUCe Elevated Left Atrial Pressure in Patients with Heart 97 
Failure) was designed to evaluate the device performance and safety of a trans-catheter, transvenous 98 






Study Design 104 
The study was a multi-centre prospective, non-randomized, open label, single-arm study designed to 105 
investigate the safety and performance of a trans-catheter interatrial shunt device (IASD system II, 106 
Figure 1). The study design has been described in detail elsewhere 
15
 (clin.trials.gov #: 107 
NCT01913613).  108 
 109 
Patient population 110 
Patients with known HFPEF were eligible for study inclusion if they had evidence of chronic 111 
symptomatic HF (NYHA class II-IV), a left ventricular ejection fraction >40% and an elevated 112 
pulmonary capillary wedge pressure (PCWP) at rest (>15mmHg) or during exercise (>25mmHg) 113 
measured by right heart catheterization. Patients with significant right ventricular dysfunction including 114 
a central venous pressure (CVP) >14 mmHg and tricuspid annular plane systolic excursion (TAPSE) 115 
<14 mm were excluded.  116 
 117 
Cardiac catheterization and device implantation 118 
All patients underwent right heart catheterization with assessment of cardiac output and central 119 
haemodynamics (right atrial pressure, pulmonary artery pressure and PCWP) at rest and during 120 
supine bicycle exercise before (during a separate screening evaluation) and 6 months after device 121 
implantation. Following baseline haemodynamic measurements, symptom-limited supine bicycle 122 
exercise commenced at 20 Watts (W) with 20W increments every 3 minutes until the patient achieved 123 
maximum effort. Blood samples were collected from the pulmonary artery and vena cavae at baseline 124 
and follow-up study to measure oxygen saturation and to evaluate left to right shunting as reflected by 125 
the Qp:Qs ratio. Device insertion was conducted within 45 days of screening.  Implantation was 126 
performed percutaneously via the femoral vein on a separate occasion
16
. Standard trans-septal 127 
puncture of the interatrial septum was performed using the operator’s preferred technique including 128 
fluoroscopy and transoesophageal or intra-cardiac echocardiography and the device was positioned 129 
using an “over the wire technique”. Patients not taking oral anticoagulants were treated with aspirin 130 
(75 – 325 mg daily) indefinitely, and clopidogrel (75 mg daily) for 6 months. Patients treated with oral 131 
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anticoagulants continued on oral anticoagulants after the procedure. Endocarditis prophylaxis was 132 
advised for a minimum of 6 months post implant.  133 
 134 
Device performance, safety and efficacy end points at follow-up 135 
The primary objectives of the study were to assess device performance and safety. The study sample 136 
size was calculated as that required to demonstrate a device and procedure safety profile to other 137 
comparable procedures
15
 .  The primary device performance end-points were defined as the 138 
proportion of patients with successful device implantation, the percentage of patients with a reduction 139 
in PCWP at 6 months either at rest or during exercise compared to baseline, and the presence of 140 
persistent left to right trans-device blood flow at 6 months. The primary safety end-points were peri-141 
procedural and 6 month major adverse cardiac and cerebrovascular events (MACCE) defined as 142 
death, stroke, myocardial infarction or a systemic embolic event (excluding pulmonary 143 
thromboembolism), or need for cardiac surgical device removal within 6 months. Echocardiograms 144 
performed at the implanting site per protocol were analysed at an independent core laboratory. 145 
Secondary outcome measures included the incidence of major adverse events, heart failure 146 
hospitalization over the entire study together with changes in echocardiographic parameters, 147 
functional capacity (6 minute walk), natriuretic peptides and quality of life assessments (Minnesota 148 
Living with Heart Failure Questionnaire, MLWHFQ). All patients gave written informed consent and 149 
the protocol was approved by each institutional ethics committee, and competent authorities. 150 
 151 
Statistical methods 152 
Normally distributed data are presented as mean ± standard deviation and non-parametric data as 153 
median and interquartile range. As appropriate a paired t test or Wilcoxon matched pairs sign-rank 154 
test were used to compare follow-up to baseline data. The null hypothesis was rejected at p<0.05. 155 
 156 
Role of the funding source 157 
The study was funded by Corvia Medical Incorporated. Data collection and analysis was performed by 158 
Medpass International Limited, Windsor House, Worcestershire, United Kingdom. Interpretation of the 159 
results and preparation of the manuscript was the responsibility of the steering committee and 160 
principal investigators. Corvia played no role in the collection, analysis, interpretation of data or the 161 
 6 






Study population characteristics 167 
Of 102 patients enrolled from 21 centres, 68 met the inclusion and exclusion criteria. The commonest 168 
reasons for exclusion were failure to meet the haemodynamic inclusion criteria (PCWP too low in 22, 169 
and CVP too high in 3 patients). One patient was excluded for each of the following reasons: LVEF< 170 
40%; cardiac index < 2.0 L/min/m
2
; renal impairment; cerebrovascular disease; tricuspid regurgitation; 171 
mitral regurgitation; coronary disease; elevated pulmonary vascular resistance; and pneumonia. Two 172 
patients withdrew after qualification. Implantation of the IASD system was abandoned in two patients 173 
and was successful in 64. The baseline demographics of those implanted are shown in Table 1. 174 
Consistent with the HFPEF phenotype, the PCWP increased during exercise from 18±5 to 35±8 175 
mmHg (p<0.0001), the mean pulmonary pressure rose from 25±7 to 44±9 mmHg (p<0.0001) and the 176 
mean right atrial pressure increased from 9±4 to 18±5 mmHg (p<0.0001). The cardiac output rose 177 
from 5.6±1.7 to 8.4±2.7 L/min (p<0.0001). The mean exercise time during haemodynamic testing was 178 
7.3±3.1 minutes at a workload of 43±18 Watts. 179 
 180 
Primary safety end point 181 
No patient experienced a peri-procedural or major adverse cardiac or cerebrovascular event 182 
(MACCE), including death, stroke, myocardial infarction, pulmonary or systemic embolism or need for 183 
cardiac surgical intervention for device related complications, during six months follow-up. One patient 184 
declined a final clinical follow-up due to non-cardiovascular illness. 185 
 186 
Primary device performance end points 187 
The implant procedure was not completed due to a trans-septal puncture complication without further 188 
sequelae in one patient, and perceived unsuitable atrial septal anatomy in another. In three patients 189 
the initial device was removed due to unsuitable position (n=2) or a suspected small mobile thrombus 190 
in the right atrium (n=1) with a second device deployed in all three without incident.  Sixty patients 191 
underwent right heart catheterisation for haemodynamic evaluation at 6 months, and exercise 192 
haemodynamic responses were evaluated in 59 patients. At follow-up, 42 patients (71%) met the 193 
primary device performance definition of a reduction in PCWP either at rest or during exertion as 194 
compared to their baseline values (n = 37). Of these patients, 52% (31/60) had a reduction in PCWP 195 
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at rest, 58% 34/59) had a lower PCWP during exertion and 39% (23/59) fulfilled both criteria. All 196 
patients with adequate echocardiographic image quality (n=50), had evidence of left to right flow 197 
through the device by colour flow Doppler flow at 6 months. Right to left flow by colour flow Doppler 198 
was not observed. Haemodynamic and echocardiographic data were evaluated in a blinded manner 199 
in core laboratories. 200 
 201 
 202 
Secondary efficacy and safety end points  203 
By six months, median [IQR] NYHA class had improved from 3 [2-3] to 2 [2-3] (p<0.001), MLWHF 204 
score from 49±20 to 36±23 (p<0.0001), 6 minute walk distance from 313±105 to 345±106 metres, 205 
p=0.0023) and supine exercise duration at the time of right heart catheterisation from 7.3±3.1 to 206 
8.2±3.4 minutes (p=0.0275; Figure 2).  207 
 208 
At the 6 month follow up evaluation, there was a modest but significant increase in cardiac output at 209 
rest measured by thermodilution, consistent with increased right sided cardiac output due to the inter-210 
atrial shunt (Figure 3). Oximetry was used to estimate left ventricular forward cardiac output at rest, 211 
which showed no change from baseline to follow-up (4.6±1.2 vs 4.8±1.3 L/min, p=0.43). The 212 
augmentation in thermodilution right-sided cardiac output during exercise was similar at baseline (rest 213 
vs exercise: 5.5±1.6 vs 8.7±2.6 L/min, p<0.0001) and 6 months (rest vs exercise: 6.7±1.5 vs 10.2±2.7 214 
L/min, p<0.0001). Whilst resting PCWP was similar compared to the baseline study (17±5 vs 215 
17±7mmHg, p=0.24), exercise PCWP was reduced, both at 20W (32±8 vs 29±9, p=0.0124) and at 216 
peak exercise (34±8 vs.32±8, p=0.0255) (Figure 3). At peak exertion, PCWP normalised for workload 217 
was lower at follow-up compared to baseline (69±40 vs 84±45 mmHg/Watt/kg, p=0.0001). There was 218 
no change in pulmonary vascular resistance (baseline vs. 6 months: 1.3±0.3 vs. 1.1±0.2 Wood units, 219 
p=0.36). Right atrial pressure was higher at follow-up than at baseline (9±4 vs. 11±5 mmHg, 220 
p=0.0270). At baseline the gradient between PCWP and RA was 8±4 mmHg, which fell to 6±3 mmHg 221 
at 6 months post IASD implantation (p<0.0001). Similarly, at peak exercise the gradient between 222 
PCWP and RA was 17±8 mmHg and this fell to 12±6 mmHg at 6 months post IASD implantation 223 
(p=0.0002).Consistent with the echocardiographic evaluation of device patency, measurement of 224 
oxygen saturations during cardiac catheterization confirmed a rise in pulmonary artery oxygen 225 
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saturation from 69±6 to 75±5% (p<0.0001) with a left-to-right shunt (pulmonary/systemic flow at 226 
baseline vs. 6 months: 1.06±0.32 6 months vs. 1.27±0.20; p=0.0004).  227 
 228 
Echocardiography demonstrated small changes in chamber volumes at follow-up compared to 229 
baseline. The LV diastolic volume index decreased from 68±13 to 62±17 ml/m
2
 (p=0.004) whilst the 230 
right ventricular end diastolic volume index increased from 22±9 to 27±11 ml/m
2
 (p<0.001). The RA 231 
volume index increased from baseline to follow-up: 35±17 vs 40±22 ml/m
2
 (p=0.014) whilst the LA 232 
volume index (34±17 vs 35±22 ml/m
2
 was unchanged. Tricuspid annular plane systolic excursion 233 
(TAPSE) was also unchanged (20±4 vs. 20±4 mm). 234 
 235 
Compared with baseline, there was a small reduction in body weight (90.1±18.3 to 88.4±18.6 kg/m
2
, 236 
p=0.008). Neither NT-proBNP (median, IQR; 377 (222-925) vs. 382 (170-1075) pg/mL) nor eGFR 237 
(62±21 vs 61±20 ml/min/m
2
) changed during the study. In the 6 months prior to trial participation, 20% 238 
(13/64) of patients required hospitalization for heart failure compared to 14% (9/63) in the 6 months 239 
subsequent to enrolment. The median dose of frusemide at baseline was 35mg/day (IQR 12.5 – 240 
92.5). At 6 months the median dose was 35 mg/day (IQR 12.5 – 180), however the difference 241 
between groups was significant (by paired sign rank test, p=0.0176). The median difference in 242 
frusemide dose between 6 months and baseline was 0mg (IQR: 0 – 15mg/d), and only 7 patients had 243 
an increase in their diuretic dose. Because the difference was small, it is unlikely that a change in 244 
dose accounted for the observed effects. 245 
  246 
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Discussion 247 
In this open-label study of a novel trans-catheter interatrial shunt device, developed for the 248 
management of patients with HFPEF, we observed reductions in left atrial pressure during exercise 249 
with improvements in functional capacity and quality of life 6 months after implantation. The procedure 250 
was well tolerated, and echocardiographic and oximetric studies demonstrated the presence of 251 
continuing device patency and left to right shunting at 6 months.  252 
 253 
HFPEF is characterized by complex cardiovascular pathophysiology. Originally, attention focussed on 254 
the role of diastolic dysfunction 
11,12
 as a cause of a rapid rise in left ventricular diastolic and left atrial 255 
pressure during exertion. The underlying myocardial biology of HFPEF is controversial. It has been 256 
ascribed to myocardial fibrosis 
17
, myocyte hypertrophy and altered post-translation modification of 257 
myocardial proteins such as titin 
18,19
. Additionally, many other factors contribute to the clinical profile 258 
of HFPEF patients, including hypertension 
4,6
 myocardial and systemic microvascular dysfunction 
20,21
 259 
and left ventricular long-axis systolic dysfunction 
22
, as well as extra-cardiac co-morbidities such as 260 
renal insufficiency 
23
, anaemia, obesity and sleep apnoea 
24
.  261 
 262 
To date, pharmacological management of HFPEF has not reduced morbidity and mortality. Even the 263 
impact of pharmacological therapy on symptoms or exercise capacity is uncertain. Therapeutic failure 264 
may reflect both diagnostic uncertainty and the complexity of the disorder. Identifying a homogenous 265 
patient population has also been challenging in HFPEF 
25
. In the current study, we used invasive 266 
hemodynamic assessment both at rest and during exertion to identify, reliably, patients with objective 267 
evidence of impaired diastolic reserve. The use of exercise PCWP as a study end-point has only been 268 
reported once previously to assess the effectiveness of an intervention in HFPEF patients 
26
, although 269 




The current study was an open-label non-randomised study, thus we are unable to exclude a placebo 272 
effect. However, reduction in exercise pulmonary capillary wedge pressure is consistent with atrial 273 
decompression and the reduction in left ventricular end diastolic volume consistent with LV 274 
decompression. Peak exercise PCWP was reduced following shunt implantation despite an increase 275 
in exercise capacity and accordingly, PCWP normalized to workload, a measurement that has 276 
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predicted mortality in patients with HFPEF 
13
, was reduced. Left atrial decompression should lead to a 277 
reduction in left atrial volumes but this may have been attenuated by the increased venous return to 278 
the left atrium due to the shunt flow. Alternatively, the observation period may have been too short or 279 
a larger sample size may be required to detect changes, particularly in the setting of chronic atrial 280 
remodelling and atrial fibrillation. There were small increases in right atrial pressure and volume and 281 
right ventricular volume which may represent the effect of shunting per se or an increase in circulating 282 
volume. The latter possibility is unlikely as body weight fell during the study period. There was a 283 
modest increase in right sided cardiac output consistent with volume loading, whilst left sided output, 284 
as measured from oximetric observations was unchanged. The long-term sequelae of modest 285 
increases in right ventricular output are not known and therefore we excluded patients with significant 286 
right ventricular dysfunction. 287 
 288 
Current guidelines for the diagnosis of HFPEF include evidence of elevated natriuretic peptides and 289 
echocardiographic measures of elevated filling pressures, as reflected by the E/e’ ratio 
27
. In this 290 
study, device implantation was not accompanied by reduction in either of these non-invasive 291 
measurements. This finding may be explained by the fact that these measures were conducted at rest 292 
or by the relatively modest overall reduction in filling pressures. 293 
 294 
Taken together the current open-label non-randomized study demonstrates that trans-catheter trans-295 
venous placement of an interatrial shunt device is feasible and may be associated with improvements 296 
in exercise haemodynamics, functional capacity and quality of life. These findings require validation in 297 
a randomized controlled blinded study.  298 
 299 
 300 
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FIGURE LEGENDS 416 
 417 
Figure 1. Schematic diagram of interatrial septal device (IASD) allowing communication between left 418 
and right atria (left panel) and echocardiographic image demonstrating Doppler colour flow from left to 419 
right atrium (right panel). 420 
 421 
Figure 2. Bar graphs showing New York Heart Association Class, Minnesota Living with Heart Failure 422 
score, six minute walk test distance and exercise time during right heart catheterisation at baseline 423 
and follow-up. 424 
 425 
Figure 3. Bar graphs showing cardiac output and pulmonary capillary wedge pressure (PCWP) at rest 426 
and exercise at baseline and follow-up. PCWP normalized to workload is also presented.  427 
 428 
 429 
  430 
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Table 1. Patient characteristics at baseline 431 
 432 

































  466 
Variable  
Age (years) 69±8 
Gender (n, M/F) 22/42 
NYHA Class (n, II/III/IV) 18/46/0 
BMI, kg/m2 33±6 
eGFR (ml/min/1.73m2) 62±21 
Haemoglobin (g/L) 133±5 
Co-Morbidities n(%)  
 Diabetes 21 (33) 
 Hypertension  52 (81) 
 Atrial fibrillation  23 (36) 
 CAD  23 (36) 
Echocardiography  
 LV end diastolic volume index (ml/m2) 68±13 
 LVEF (%) 47±7  
 LV mass index (g/m2) 119±36 
 LA diastolic volume index (ml/m2) 34±17  
 RV diastolic volume index (ml/m2) 22±9 
 RA volume index (ml/m2) 35±17 
 E/A ratio 1.3±0.8 
 E/e’ ratio 13.9±5.9 
 TAPSE (mm) 20±4 
NT-Pro BNP (pg/mL)* 377 (222-925) 
 
Resting Haemodynamics  
9±4 





 Mean RA Pressure (mmHg) 9±4 
 ean PA Pre sure ( mHg) 25±7 
 Mean PCWP (mmHg) 17±5 
 Cardiac output (L/min) 5.5±1.6 
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